VectivBio_Logo_RGB_Color.png
VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications
April 21, 2022 07:15 ET | VectivBio AG
BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
Logo 1.png
Dutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital Hyperinsulinism
April 21, 2022 02:00 ET | Xinvento BV
AMSTERDAM, April 21, 2022 (GLOBE NEWSWIRE) -- Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces today the completion of a seed funding...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Plan for Chief Financial Officer Transition
April 20, 2022 16:30 ET | Travere Therapeutics, Inc.
Laura Clague to step-down as CFO in August 2022 and retire in 2023 Chris Cline, Travere SVP of Investor Relations & Corporate Communications, to assume position of chief financial officer in...
SERB acquires the rights to Xermelo® outside US and Japan for Carcinoid Syndrome Diarrhoea
April 04, 2022 02:08 ET | BTG Specialty Pharmaceuticals
Paris, April 04, 2022 (GLOBE NEWSWIRE) -- SERB is pleased to announce it has acquired the rights from Ipsen to commercialize Xermelo® (telotristat ethyl) in Europe and other countries outside the US...
Saniona Announces Strategic Program Prioritization and Restructuring to Streamline Operational Costs
March 29, 2022 10:00 ET | Saniona AB
PRESS RELEASE March 29, 2022 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced a strategic program reprioritization and restructuring...
Saniona tillkännager strategisk programprioritering och omstrukturering för att minska rörelsekostnader
March 29, 2022 10:00 ET | Saniona AB
PRESSMEDDELANDE 29 mars 2022 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, tillkännager idag en strategisk omprioritering bland...
Alexion Charitable Foundation Awards Give an Hour Grant Offering Hope and Healing
March 29, 2022 08:00 ET | Give an Hour
BETHESDA, Md., March 29, 2022 (GLOBE NEWSWIRE) -- Give an Hour® will offer much-needed mental health and emotional well-being support to caregivers in the rare disease community through a one-year,...
download.png
Inspirational Child with MLD, Calliope Joy, Passes Away
March 25, 2022 09:37 ET | The Calliope Joy Foundation
BALA CYNWYD, Pa., March 25, 2022 (GLOBE NEWSWIRE) -- Calliope ‘Cal’ Joy Carr, 12, who inspired a global movement to raise awareness of and funding for rare diseases, passed away yesterday, Thursday,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 16, 2022 16:21 ET | Catalyst Pharmaceuticals, Inc.
Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
March 11, 2022 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...